Cross-Sector entity
pharma is the sole category represented across all 1 tracked stories. Japanese Encephalitis Vaccine is most often covered alongside KM Biologics Co., Ltd., which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Japanese Encephalitis Vaccine appears in 1 tracked Cross-Sector story from August 24, 2026.
1 verified story tracked
Last mentioned: 21h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Japanese Encephalitis Vaccine is most often covered alongside KM Biologics Co., Ltd., which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Japanese Encephalitis Vaccine appears in 1 tracked Cross-Sector story from August 24, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Japanese Encephalitis Vaccine. Shared-story counts are live from our verified record — not editorial picks.
Meiji Seika Pharma will transfer manufacturing technology for its Japanese encephalitis vaccine, developed and marketed by KM Biologics in Japan, to Serum Institute of India. SII engineers have already visited Japan, and the Indian firm expects to file for regulatory approval as early as 2027.
Source: news.webindia123.com · aninews.in
